Other LMNA gene mutations, such as Dunnigan-type familial partial lipodystrophy (FPLD2), can lead to proatherogenic metabolic disturbances such as dyslipidemia, hyperinsulinemia, hypertension and diabetes. Here, LMNA is linked to hyperinsulinism.